Coronary artery disease and diabetes. Secondary prevention needs more attention

Postgraduate Medicine

Volumn 105, Issue 2, 1999, Pages 66-80

  Bohannon, Nancy J V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; HUMAN; HYPERTENSION; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; SMOKING;

EID: 0033018028     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.02.533     Document Type: Conference Paper

References (35)

1. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J 1985;110(5):1100-7
2. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract 1992;17(2):111-23
3. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43(8):960-7
4. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991;90(2A):56S-61S
5. Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991;14(7):537-43
6. Gordon T, Castelli WP, Hjortland MC, et al. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women: the Framingham study. Ann Intern Med 1977;87(4):393-7
7. Bierman EL. George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 1992;12(6):647-56
8. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2): 434-44
9. Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? Lancet 1995;346(8967):100-3
10. Katz RJ, Ratner RE, Cohen RM, et al. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 1996;45(6):736-41
11. Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985;701:38-52
12. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991;14(6):461-9
13. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996;124(1 Pt 2):110-6
14. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19(S1):S54-61
15. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2(2):131-41
16. Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994;74(7):735-7
17. Grant PJ. The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996;19(1):64-6
18. Lam KS, Cheng IK, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38(5):604-9
19. Mulec H, Johnsen SA, Wiklund O, et al. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993;22(1): 196-201
20. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32(5):300-4
21. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21(1):179-82
22. Dunn FL, Pietri A, Raskin P. Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus. Ann Intern Med 1981;95(4):426-31
23. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15(7):820-5
24. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-20 [Erratum, Diabetes Care 1997;20(6):1048]
25. Haffner SM, Alexander CM, Boccuzzi SJ, et al. Improved survival, reduced major-coronary events and fewer revascularizations in simvastatin-treated 4S patients with impaired fasting glucose. Diabetes, Suppl 1, 1998;47:A54
26. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9
27. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995;333(9): 541-9
28. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268(10):1292-300
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308(6921):81-106 [Erratum, BMJ 1994;308(6943):1540]
30. 3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278(6):479-84
31. Kleiman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glucoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial: EPILOG investigators. Circulation 1998;97(19):1912-20
32. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996;77(15):1273-7
33. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26(1):57-65
34. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes insulin-glucose in acute myocardial infarction. Eur Heart J 1996;17(9):1337-44
35. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314(7093):1512-5